New Pancreatic Cancer Drugs Double Survival Time

For the first time in four decades, doctors have something genuinely hopeful to tell pancreatic cancer patients.

Pancreatic cancer has long been medicine's toughest opponent. Only one in 10 people survive more than five years after diagnosis, and rates have been climbing worldwide, especially among younger adults. It's projected to become the second deadliest cancer in developed countries soon.

"There hasn't been any medical progress for 40 years," says Patrick Mehlen, a researcher at France's Leon Berard cancer centre. But increased funding and attention over the past decade is finally changing that reality.

Last week, Revolution Medicines announced groundbreaking results for their experimental pill daraxonrasib. The drug targets a protein called KRAS, which helps tumors grow.

Half the patients taking daraxonrasib survived more than 13 months. That's twice as long as those receiving standard chemotherapy alone.

Doubling life expectancy might not sound revolutionary for other diseases, but for pancreatic cancer it's unprecedented. Former Nebraska Senator Ben Sasse knows this firsthand.

Diagnosed with stage four metastasized pancreatic cancer in late 2024, doctors gave him three to four months to live. After starting daraxonrasib, he told the New York Times he's "doing a heck of a lot better" than he was at Christmas.

He was honest about the side effects, which left his face peeling and bloody. But the extra time matters.

Revolution Medicines plans to apply for U.S. approval soon, with detailed trial results coming at the ASCO cancer conference in Chicago next month.

Meanwhile, other researchers are taking different approaches. Results published Wednesday in the journal Nature describe an antibody called NP137 that doesn't attack tumors directly.

Instead, it stops cancer cells from becoming resistant to other treatments like chemotherapy. In early trials with 43 patients, people lived several months longer than typical survival rates.

"We're giving people an average of six months more, which is significant for this disease," Mehlen said. His team plans larger trials later this year, and he hopes NP137 will eventually work alongside drugs like daraxonrasib.

There's also promising news about a pancreatic cancer vaccine using mRNA technology. Developed by BioNTech and Genentech, it trained patients' immune systems to target cancer cells.

Out of 16 patients who received the vaccine, eight showed strong immune responses. Seven of those eight were still alive six years later, compared to just two of the eight whose immune systems didn't respond as strongly.

Why This Inspires

These breakthroughs represent more than just statistics. They're giving patients and families something they haven't had in generations: realistic hope and precious extra time together.

For a cancer that's killed so quickly for so long, every additional month is a victory. Researchers are finally turning the tide against one of medicine's deadliest opponents.

##